132 related articles for article (PubMed ID: 32857419)
21. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
Muñoz J; Alcaide D; Ocaña J
Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
[TBL] [Abstract][Full Text] [Related]
22. Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants.
Schwartz JB
J Am Geriatr Soc; 2016 Oct; 64(10):1996-2002. PubMed ID: 27549687
[TBL] [Abstract][Full Text] [Related]
23. A general empirical model for renal drug handling in pharmacokinetic analyses.
Wright DFB; Duffull SB
Br J Clin Pharmacol; 2017 Sep; 83(9):1869-1872. PubMed ID: 28419522
[TBL] [Abstract][Full Text] [Related]
24. The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study.
Cristea S; Krekels EHJ; Rostami-Hodjegan A; Allegaert K; Knibbe CAJ
AAPS J; 2020 Jun; 22(4):87. PubMed ID: 32566984
[TBL] [Abstract][Full Text] [Related]
25. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
26. Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006-2018).
Seo Y; Pacifici E
Vaccine; 2020 Nov; 38(47):7485-7489. PubMed ID: 33059971
[TBL] [Abstract][Full Text] [Related]
27. Principles and clinical application of assessing alterations in renal elimination pathways.
Tett SE; Kirkpatrick CM; Gross AS; McLachlan AJ
Clin Pharmacokinet; 2003; 42(14):1193-211. PubMed ID: 14606929
[TBL] [Abstract][Full Text] [Related]
28. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
[TBL] [Abstract][Full Text] [Related]
29. Advancing structured decision-making in drug regulation at the FDA and EMA.
Angelis A; Phillips LD
Br J Clin Pharmacol; 2021 Feb; 87(2):395-405. PubMed ID: 32529733
[TBL] [Abstract][Full Text] [Related]
30. US FDA/EMA harmonization of their bioanalytical guidance/guideline and activities of the Global Bioanalytical Consortium.
Garofolo F; Michon J; Leclaire V; Booth B; Lowes S; Viswanathan CT; Welink J; Haidar S; Teixeira Lde S; Tang D; Desilva B
Bioanalysis; 2012 Feb; 4(3):231-6. PubMed ID: 22303826
[TBL] [Abstract][Full Text] [Related]
31. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
Levey AS; Inker LA; Matsushita K; Greene T; Willis K; Lewis E; de Zeeuw D; Cheung AK; Coresh J
Am J Kidney Dis; 2014 Dec; 64(6):821-35. PubMed ID: 25441437
[TBL] [Abstract][Full Text] [Related]
32. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
Leo CP; Hentschel B; Szucs TD; Leo C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069837
[TBL] [Abstract][Full Text] [Related]
33. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
34. How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views.
Tafuri G; Stolk P; Trotta F; Putzeist M; Leufkens HG; Laing RO; De Allegri M
Ann Oncol; 2014 Jan; 25(1):265-9. PubMed ID: 24356637
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
37. Paediatric Medicines - Regulatory Drivers, Restraints, Opportunities and Challenges.
Vieira I; Sousa JJ; Vitorino C
J Pharm Sci; 2021 Apr; 110(4):1545-1556. PubMed ID: 33421435
[TBL] [Abstract][Full Text] [Related]
38. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Sudsakorn S; Bahadduri P; Fretland J; Lu C
Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
[TBL] [Abstract][Full Text] [Related]
39. Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study.
Langhof H; Chin WWL; Wieschowski S; Federico C; Kimmelman J; Strech D
Br J Pharmacol; 2018 Nov; 175(22):4229-4238. PubMed ID: 30153701
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women.
Alidjanov JF; Naber KG; Pilatz A; Radzhabov A; Zamuddinov M; Magyar A; Tenke P; Wagenlehner FM
World J Urol; 2020 Jan; 38(1):63-72. PubMed ID: 31004204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
